National and Kapodistrian University of Athens
Διερεύνηση της απορρύθμισης των γονιδίων HER2/neu και PTEN στο μη μικροκυτταρικό καρκίνο του πνεύμονα
Abstract
dc:descriptionBackround: HER2/neu overexpression due to gene amplification is an important factor in breast cancer modifying the sensitivity to anti-HER-2/neu monoclonal antibody therapy. The clinical significance of HER2/neu expression in non-small-cell lung carcinoma (NSCLC) is currently under evaluation. The tumor suppressor gene PTEN negatively regulates the HER2/PI3K/Akt signalling pathway and plays an important role in cell cycle regulation and apoptosis. Although the loss of PTEN is not a rare event in NSCLC its prognostic role is still not well established. Purpose: The purpose of this study was to evaluate the role of HER2/neu oncogene in both gene and protein level and the role of PTEN tumor suppressor gene in protein level in NSCLC. Emphasis was given to investigate the role of simultaneous HER2 and PTEN protein expression alterations in relation to prognosis of NSCLC patients. Materials and methods: Surgical specimens were obtained from a total of 61 patients with NSCLC who underwent a surgical resection. Immunohistochemistry was performed by the use of anti-HER2/neu monoclonal antibody (TAB 250) and anti-PTEN polyclonal antibody (PN 37). Chromogenic in situ hybribization was applied based on the use of HER2/neu gene and chromosome 17 centromeric probes. Protein expression levels were evaluated using an image analysis system and finally statistical analysis was performed. Patients followed-up in a period of 34 to 41 months after the operation. Results: HER2 overexpression (2+/3+ score) was detected in 17 (27.87%) patients. Additionally, loss of PTEN expression was observed in 24 (39.34%) cases, low expression in 29 (47.54%) and overexpression in 8 (13.12%) cases. Gene analysis identified 4/61(6.56%) HER2/neu low-level gene amplified cases. Chromosome 17 analysis detected aneuploidy in 2/61(3.28%) cases. Simultaneous HER2 overexpression and PTEN low/loss of expression were correlated to the occurrence of metastases. (71,43% vs 36,17% p=0.03). Strong relationship between the number of positive regional lymph node stations during the time of operation and simultaneous deregulation of the two genes was revealed (p=0.04). Multivariate analysis determined that HER2 overexpression was associated with an increasing risk of developing metastases (OR: 4.3; 95%CI: 1.2-15.9; p: 0.03) while PTEN overexpression was associated with lower risk to develop metastases (OR: 0.1; 95%CI: 0.1, 1.0; p: 0.05). According to the findings of survival analysis, poor survival was significantly associated with the occurrence of metastasis (p=0.002), increasing tumor size (p=0.02), pTNM stage (p=0.01) and lymph node status (p=0.01). Conclusions: Simultaneous HER2 and PTEN deregulation is a significant genetic event that is likely to offer in the progression of NSCLC.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2013
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Panagiotou, Ioannis
- Παναγιώτου, Ιωάννης
Subjects
dc:subject × 16- Πρωτο-ογκογονίδια
- Ογκοκατασταλτικό γονίδιο
- Μη μικροκυτταρικός καρκίνος πνεύμονα
- Ανοσοϊστοχημεία
- Χρωμογόνος υβριδισμός
- Proto-oncogenes
- Tumor suppressor genes
- Non-small cell lung cancer
- Immunohistochemistry
- Chromogenic in situ hybridization
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Κλινική Ιατρική
- Medical and Health Sciences
- Basic Medicine
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/29707